1–3 of 3 results for Neil M. Bressler
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
DRCR.net Anti-VEGF Comparative Effectiveness Trial for Diabetic Macular Edema
Member Podcasts
Retinal Vascular Disease Take-Home Panel
2019